SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression

Table 1

Correlation of SHMT2 staining with CRC patients’ pathological and clinical features.

Variables	SHMT2 staining			P values
	All cases (n = 201)	Negative (n = 37)	Positive (n = 164)
Age (yr)^d				0.360^a
≤63	95	20 (21.1%)	75 (78.9%)
>63	106	17 (16.0%)	89 (84.0%)
Gender				0.509^a
Male	133	19 (16.8%)	94 (83.2%)
Female	88	18 (20.5%)	70 (79.5%)
TNM staging				<0.022^c
I	17	7 (41.2%)	10 (58.8%)
II	76	17 (22.4%)	59 (77.6%)
III	84	10 (11.9%)	74 (88.1%)
IV	24	3 (12.5%)	21 (87.5%)
Lymph node metastasis
N0	96	24 (25.0%)	72 (75.0%)	0.021^a
N1+2	105	13 (12.4%)	92 (87.6%)
Distal metastasis				0.426
M0	177	34 (19.2%)	143 (80.8%)
M1	24	3 (12.5%)	21 (87.5%)

^aMann-Whitney U test, ^bKruskal-Wallis, and ^cSpearman. ^dMedian age at operation. ^eProximal colon tumors are those arising in the cecum, ascending colon, hepatic flexure, or transverse colon; distal colon tumors are those arising in the splenic flexure, descending colon, or sigmoid colon; and rectal tumors are those arising in the rectosigmoid or rectum. CEA, carcinoembryonic antigen; CA242, carbohydrate antigen 242. p < 0.05 is considered as statistically significant.